Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
an inactivated whole virion H5N1 vaccine, adjuvanted · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| an inactivated whole virion H5N1 vaccine, adjuvanted | BIOLOGICAL | - |
Inclusion Criteria: * Males and females, age from 18 to 60 years old; * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process; * Able and willing to complete the informed consent process. Exclusion Criteria: * Woman who is breast-feeding or...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
It is an investigational pandemic influenza vaccine developed by Sinovac Biotech, Ltd. It uses inactivated whole virion H5N1 virus with an adjuvant and is intended for the prevention of influenza. It is in Phase 1 clinical development and has been studied in healthy adult volunteers.
It is being developed for the prevention of influenza caused by the H5N1 avian influenza virus. The vaccine is intended for use in healthy adults. Its only recorded clinical study enrolled healthy volunteers aged 18 years and older in China.
Sinovac Biotech, Ltd. is the developer of the inactivated whole virion H5N1 vaccine, adjuvanted. The company trades under the ticker SVA. Sinovac is a vaccine-focused biopharmaceutical company, and this H5N1 pandemic influenza candidate is one of its infectious disease programs.
It is in Phase 1 clinical development. The single recorded trial, NCT00356798, was a Phase 1 study that has been completed. No later-phase trials are listed, so the vaccine remains investigational and is not an approved product.
One trial is recorded: NCT00356798, titled a randomized, double blinded, placebo controlled clinical trial of pandemic influenza inactive vaccine in healthy subjects. It was a completed Phase 1 study with 120 enrolled participants, conducted in China, in adults aged 18 years and older.
NCT00356798 was a randomized, double blinded, placebo controlled Phase 1 trial. It enrolled 120 healthy volunteers aged 18 years and older in China and has been completed. The study evaluated the pandemic influenza inactivated vaccine in this healthy adult population.